Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.56 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7716642 | 0.91 | CYP4F2 (0.47) | CYP4F2CYP4A11GRM4MEN1KMT2A | |
| SCHEMBL2048398 | 0.87 | CYP4F2 (0.42) | CYP4F2CYP4A11GRM4MEN1KMT2A | |
| SCHEMBL2239463 | 0.86 | CYP4F2 (0.41) | CYP4F2CYP4A11GRM4ALDH1A1LPAR3 | |
| SCHEMBL2047336 | 0.84 | CYP4F2 (0.47) | CYP4F2CYP4A11GRM4MEN1KMT2A | |
| SCHEMBL2237290 | 0.83 | GRM4 (0.41) | CYP4F2CYP4A11GRM4LPAR3LPAR2 | |
| SCHEMBL2238007 | 0.83 | CYP4F2 (0.42) | CYP4F2CYP4A11GRM4ATMALDH1A1 | |
| SCHEMBL2047371 | 0.82 | CYP4F2 (0.49) | CYP4F2CYP4A11MEN1KMT2AATM | |
| SCHEMBL2044329 | 0.82 | CYP4F2 (0.49) | CYP4F2CYP4A11MEN1KMT2AATM | |
| SCHEMBL2049658 | 0.82 | CYP4F2 (0.49) | CYP4F2CYP4A11MEN1KMT2AATM | |
| SCHEMBL2047345 | 0.82 | CYP4F2 (0.49) | CYP4F2CYP4A11MEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080573-A | Flame-retardant phenolic aldehyde/glass fiber composite board, preparation method and application | — | 2026-05-26 | — | — | CN | claimed |
| CN-122080573-A | Flame-retardant phenolic aldehyde/glass fiber composite board, preparation method and application | — | 2026-05-26 | — | — | CN | disclosed |
| CN-120895758-A | Electrolyte with phosphonate as organic additive and water-based zinc ion battery | 中国科学院福建物质结构研究所 | 2025-11-04 | — | — | CN | disclosed |
| US-12159967-B2 | Nonaqueous electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-12-03 | — | — | US | disclosed |
| US-20240128511-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-04-18 | — | — | US | disclosed |
| US-11942601-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-03-26 | — | — | US | disclosed |
| CN-115536719-B | Synthesis method of high-purity plant source 7-ketolithocholic acid | 江苏佳尔科药业集团股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-4318719-A2 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2024-02-07 | — | — | EP | disclosed |
| EP-4030524-B1 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20230343990-A1 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-10-26 | — | — | US | disclosed |
| EP-1315735-A4 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1482896-A2 | AMINOALKYLPHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1482895-A2 | AMINOALKYLPHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074008-A2 | AMINOALKYLPHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003073986-A2 | AMINOALKYLPHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-1315735-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | Merck & Co., Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6437165-B1 | USEFUL FOR TREATING IMMUNE MEDIATED DISEASES AND CONDITIONS, SUCH AS BONE MARROW, ORGAN AND TISSUE TRANSPLANT REJECTION. | MERCK & CO., INC. | 2002-08-20 | — | — | US | disclosed |
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | MERCK & CO., INC. | 2002-07-11 | — | — | US | disclosed |
| WO-2002018395-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO., INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| US-4278791-A | CORROSION RESISTANCE, WETTING AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | ALPP, PPIP5K2, ALPI | CYP4F2 345/4885CYP4A11 873/4885GRM4 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.